OptiNose (OPTN) Stock Forecast, Price Target & Predictions


OverviewRevenueOwnershipFinancialsChartTranscripts

OPTN Stock Forecast


OptiNose stock forecast is as follows: an average price target of $3.00 (represents a 785.48% upside from OPTN’s last price of $0.34) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.

OPTN Price Target


The average price target for OptiNose (OPTN) is $3.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $5.00 to $1.00. This represents a potential 785.48% upside from OPTN's last price of $0.34.

OPTN Analyst Ratings


Buy

According to 5 Wall Street analysts, OptiNose's rating consensus is 'Buy'. The analyst rating breakdown for OPTN stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

OptiNose Price Target by Analyst


DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Nov 13, 2024David AmsellemPiper Sandler$1.00$0.8912.36%195.16%
May 15, 2024Thomas FlatenLoop Capital Markets$3.00$1.12167.86%785.48%
Nov 14, 2022-BMO Capital$5.00$2.01148.76%1375.80%
Jun 13, 2022David AmsellemPiper Sandler$4.00$2.6252.56%1080.64%
Row per page
Go to

The latest OptiNose stock forecast, released on Nov 13, 2024 by David Amsellem from Piper Sandler, set a price target of $1.00, which represents a 12.36% increase from the stock price at the time of the forecast ($0.89), and a 195.16% increase from OPTN last price ($0.34).

OptiNose Price Target by Period


1M3M12M
# Anlaysts112
Avg Price Target$1.00$1.00$2.00
Last Closing Price$0.34$0.34$0.34
Upside/Downside195.16%195.16%490.32%

In the current month, the average price target of OptiNose stock is $1.00, according to 1 Wall Street analyst offering twelve months forecast. The average price target represents a 195.16% increase as opposed to OptiNose's last price of $0.34. This month's average price target is down 0.00% compared to last quarter, and down -50.00% compared to last year.

Analyst Ratings Upgrades/Downgrades


DateCompanyPrevious RatingNew RatingRating Change
May 15, 2024Lake StreetBuyBuyHold
Aug 21, 2023Lake Street-BuyInitialise
Aug 21, 2023Noble Capital Markets-OutperformInitialise
Aug 21, 2023Cowen & Co.-OutperformInitialise
Nov 14, 2022BMO CapitalOutperformOutperformHold
Jun 13, 2022Piper SandlerOverweightOverweightHold
Row per page
Go to

OptiNose's last stock rating was published by Lake Street on May 15, 2024. The company gave OPTN a "Buy" rating, the same as its previous rate.

OptiNose Financial Forecast


OptiNose Revenue Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18
Revenue--------$19.86M$19.82M$19.45M$11.85M$20.86M$20.08M$20.58M$14.76M$22.51M$21.83M$18.36M$11.96M$16.35M$15.44M$10.27M$7.06M$11.08M$12.40M$6.68M$4.48M$865.00K
Avg Forecast$31.80M$27.60M$24.20M$17.70M$22.31M$22.95M$20.58M$14.90M$19.26M$18.68M$17.36M$9.85M$20.71M$23.35M$20.55M$16.71M$21.75M$23.50M$18.08M$11.17M$17.92M$14.58M$9.79M$7.72M$11.64M$8.58M$6.62M$3.80M$779.57K
High Forecast$34.53M$29.97M$26.28M$19.22M$25.28M$22.98M$20.58M$16.18M$20.92M$18.68M$18.85M$10.69M$22.49M$23.35M$20.55M$16.71M$21.75M$23.50M$18.08M$11.17M$17.92M$14.58M$9.79M$7.72M$11.64M$8.58M$6.62M$3.80M$935.48K
Low Forecast$30.26M$26.26M$23.03M$16.84M$20.75M$22.93M$20.58M$14.18M$18.33M$18.68M$16.52M$9.37M$19.71M$23.35M$20.55M$16.71M$21.75M$23.50M$18.08M$11.17M$17.92M$14.58M$9.79M$7.72M$11.64M$8.58M$6.62M$3.80M$623.65K
# Analysts11113111211111111111137798610614
Surprise %--------1.03%1.06%1.12%1.20%1.01%0.86%1.00%0.88%1.03%0.93%1.02%1.07%0.91%1.06%1.05%0.91%0.95%1.44%1.01%1.18%1.11%

OptiNose's average Quarter revenue forecast for Mar 24 based on 1 analysts is $14.90M, with a low forecast of $14.18M, and a high forecast of $16.18M. OPTN's average Quarter revenue forecast represents a -24.99% decrease compared to the company's last Quarter revenue of $19.86M (Dec 23).

OptiNose EBITDA Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18
# Analysts11113111211111111111137798610614
EBITDA--------$-4.95M$-1.69M$-4.17M$-14.37M$-8.36M$-10.61M$-15.17M$-21.14M$-11.44M$-12.57M$-19.33M$-22.01M$-19.94M$-17.39M$-22.30M$-25.68M$-22.29M$-26.15M$-24.66M$-26.22M$-28.22M
Avg Forecast$-24.50M$-21.26M$-18.64M$-13.64M$-17.19M$-17.68M$-15.86M$-11.48M$-14.84M$-14.39M$-13.38M$-7.59M$-15.96M$-18.39M$-16.18M$-18.01M$-17.13M$-18.51M$-14.24M$-23.67M$-14.11M$-11.48M$-7.71M$-26.47M$-9.17M$-6.76M$-5.21M$-26.59M$-25.13M
High Forecast$-23.31M$-20.23M$-17.74M$-12.98M$-15.99M$-17.66M$-15.86M$-10.92M$-14.12M$-14.39M$-12.73M$-7.22M$-15.18M$-18.39M$-16.18M$-14.41M$-17.13M$-18.51M$-14.24M$-18.94M$-14.11M$-11.48M$-7.71M$-21.18M$-9.17M$-6.76M$-5.21M$-21.27M$-20.10M
Low Forecast$-26.60M$-23.09M$-20.24M$-14.81M$-19.48M$-17.70M$-15.86M$-12.46M$-16.12M$-14.39M$-14.52M$-8.24M$-17.33M$-18.39M$-16.18M$-21.61M$-17.13M$-18.51M$-14.24M$-28.41M$-14.11M$-11.48M$-7.71M$-31.77M$-9.17M$-6.76M$-5.21M$-31.90M$-30.16M
Surprise %--------0.33%0.12%0.31%1.89%0.52%0.58%0.94%1.17%0.67%0.68%1.36%0.93%1.41%1.51%2.89%0.97%2.43%3.87%4.73%0.99%1.12%

undefined analysts predict OPTN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than OptiNose's previous annual EBITDA (undefined) of $NaN.

OptiNose Net Income Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18
# Analysts11113111211111111111137798610614
Net Income--------$-10.16M$-9.29M$2.63M$-18.65M$-17.33M$-14.95M$-19.40M$-25.33M$-19.64M$-17.12M$-23.50M$-26.05M$-23.86M$-21.21M$-25.85M$-28.86M$-25.00M$-28.81M$-27.38M$-28.87M$-30.57M
Avg Forecast$3.49M$-1.74M$-5.23M$-8.72M$-8.22M$-9.15M$-13.49M$-18.53M$-15.12M$-16.45M$-18.92M$-24.41M$-30.47M$-28.05M$-36.54M$-21.58M$-39.18M$-53.95M$-62.79M$-28.02M$-69.57M$-78.86M$-84.39M$-29.74M$-93.43M$-106.39M$-110.91M$-29.28M$-27.22M
High Forecast$3.88M$-1.63M$-4.90M$-8.17M$-6.17M$-8.58M$-12.64M$-17.36M$-14.81M$-15.42M$-17.73M$-22.87M$-28.55M$-28.05M$-36.54M$-17.26M$-39.18M$-53.95M$-62.79M$-22.42M$-69.57M$-78.86M$-84.39M$-23.80M$-93.43M$-106.39M$-110.91M$-23.42M$-21.78M
Low Forecast$3.27M$-1.94M$-5.81M$-9.69M$-10.28M$-10.18M$-14.99M$-20.59M$-15.42M$-18.29M$-21.04M$-27.14M$-33.87M$-28.05M$-36.54M$-25.90M$-39.18M$-53.95M$-62.79M$-33.62M$-69.57M$-78.86M$-84.39M$-35.69M$-93.43M$-106.39M$-110.91M$-35.14M$-32.67M
Surprise %--------0.67%0.56%-0.14%0.76%0.57%0.53%0.53%1.17%0.50%0.32%0.37%0.93%0.34%0.27%0.31%0.97%0.27%0.27%0.25%0.99%1.12%

OptiNose's average Quarter net income forecast for Sep 23 is $-16.45M, with a range of $-18.29M to $-15.42M. OPTN's average Quarter net income forecast represents a -726.52% decrease compared to the company's last Quarter net income of $2.63M (Jun 23).

OptiNose SG&A Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18
# Analysts11113111211111111111137798610614
SG&A--------$18.96M$18.01M$20.10M$22.72M$23.31M$25.49M$29.51M$29.34M$26.34M$25.80M$27.31M$27.18M$28.11M$24.57M$25.70M$27.06M$26.55M$25.27M$26.00M$26.34M$27.82M
Avg Forecast$57.99M$50.33M$44.13M$32.28M$40.68M$41.86M$37.53M$27.17M$35.13M$34.07M$31.66M$17.96M$37.77M$42.56M$37.45M$30.45M$39.64M$42.83M$32.95M$20.35M$32.66M$26.57M$17.85M$14.07M$21.21M$15.64M$12.06M$6.93M$1.42M
High Forecast$62.97M$54.65M$47.92M$35.05M$46.11M$41.90M$37.53M$29.50M$38.15M$34.07M$34.38M$19.50M$41.01M$42.56M$37.45M$30.45M$39.64M$42.83M$32.95M$20.35M$32.66M$26.57M$17.85M$14.07M$21.21M$15.64M$12.06M$6.93M$1.70M
Low Forecast$55.18M$47.89M$41.99M$30.71M$37.84M$41.81M$37.53M$25.85M$33.43M$34.07M$30.12M$17.09M$35.94M$42.56M$37.45M$30.45M$39.64M$42.83M$32.95M$20.35M$32.66M$26.57M$17.85M$14.07M$21.21M$15.64M$12.06M$6.93M$1.14M
Surprise %--------0.54%0.53%0.64%1.27%0.62%0.60%0.79%0.96%0.66%0.60%0.83%1.34%0.86%0.92%1.44%1.92%1.25%1.62%2.16%3.80%19.58%

OptiNose's average Quarter SG&A projection for Mar 24 is $27.17M, based on 1 Wall Street analysts, with a range of $25.85M to $29.50M. The forecast indicates a 43.30% rise compared to OPTN last annual SG&A of $18.96M (Dec 23).

OptiNose EPS Forecast

Dec 25Sep 25Jun 25Mar 25Dec 24Sep 24Jun 24Mar 24Dec 23Sep 23Jun 23Mar 23Dec 22Sep 22Jun 22Mar 22Dec 21Sep 21Jun 21Mar 21Dec 20Sep 20Jun 20Mar 20Dec 19Sep 19Jun 19Mar 19Mar 18
# Analysts11113111211111111111137798610614
EPS--------$-0.00$-0.08-$-0.17$-0.18$-0.18$-0.23$-0.31$-0.29$-0.32$-0.44$-0.49$-0.46$-0.43$-0.56$-0.63$-0.58$-0.69$-0.66$-0.70$-0.81
Avg Forecast$0.02$-0.01$-0.03$-0.05$-0.05$-0.05$-0.08$-0.11$-0.09$-0.09$-0.11$-0.14$-0.17$-0.19$-0.24$-0.27$-0.26$-0.36$-0.42$-0.53$-0.46$-0.52$-0.56$-0.66$-0.62$-0.71$-0.74$-0.71$-0.65
High Forecast$0.02$-0.01$-0.03$-0.05$-0.04$-0.05$-0.07$-0.10$-0.08$-0.09$-0.10$-0.13$-0.16$-0.19$-0.24$-0.27$-0.26$-0.36$-0.42$-0.53$-0.46$-0.52$-0.56$-0.66$-0.62$-0.71$-0.74$-0.71$-0.52
Low Forecast$0.02$-0.01$-0.03$-0.06$-0.06$-0.06$-0.09$-0.12$-0.09$-0.10$-0.12$-0.16$-0.19$-0.19$-0.24$-0.27$-0.26$-0.36$-0.42$-0.53$-0.46$-0.52$-0.56$-0.66$-0.62$-0.71$-0.74$-0.71$-0.78
Surprise %--------0.00%0.88%-1.21%1.03%0.97%0.95%1.15%1.12%0.89%1.06%0.92%1.00%0.82%1.00%0.96%0.94%0.98%0.90%0.98%1.25%

According to undefined Wall Street analysts, OptiNose's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to OPTN previous annual EPS of $NaN (undefined).

OptiNose Peer Comparison by Price Target


TickerCompanyLast Closing PriceAvg Price TargetUpside/DownsideAvg Rating
PROCProcaps Group$0.53$10.001786.79%-
OPTNOptiNose$0.34$3.00782.35%Buy
KMDAKamada$5.91$20.00238.41%-
IRWDIronwood Pharmaceuticals$3.81$11.67206.30%Buy
DVAXDynavax$12.01$24.50104.00%Buy
EOLSEvolus$12.39$24.0093.70%Buy
AMPHAmphastar Pharmaceuticals$43.62$66.0051.31%Buy
ANIPANI Pharmaceuticals$55.69$79.0041.86%Buy
COLLCollegium Pharmaceutical$29.75$40.5036.13%Buy
ALKSAlkermes$27.48$36.3832.39%Hold
NBIXNeurocrine Biosciences$119.13$147.3523.69%Buy
ITCIIntra-Cellular Therapies$83.35$94.5013.38%Buy
PBHPrestige Consumer Healthcare$82.46$89.508.54%Buy
DCPHDeciphera Pharmaceuticals$25.59$26.322.85%Hold
LFCRLifecore Biomedical$7.09$6.50-8.32%Buy
PAHCPhibro Animal Health$23.75$18.67-21.39%Buy

OPTN Forecast FAQ


Is OptiNose a good buy?

Yes, according to 5 Wall Street analysts, OptiNose (OPTN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of OPTN's total ratings.

What is OPTN's price target?

OptiNose (OPTN) average price target is $3 with a range of $1 to $5, implying a 785.48% from its last price of $0.339. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will OptiNose stock go up soon?

According to Wall Street analysts' prediction for OPTN stock, the company can go up by 785.48% (from the last price of $0.339 to the average price target of $3), up by 1375.80% based on the highest stock price target, and up by 195.16% based on the lowest stock price target.

Can OptiNose stock reach $1?

OPTN's average twelve months analyst stock price target of $3 supports the claim that OptiNose can reach $1 in the near future.

What is OptiNose's current price target trend?

1 Wall Street analyst forecast a $1 price target for OptiNose (OPTN) this month, up 195.16% from its last price of $0.339. Compared to the last 3 and 12 months, the average price target increased by 195.16% and increased by 490.32%, respectively.

What are OptiNose's analysts' financial forecasts?

OptiNose's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $80.74M (high $85.02M, low $78.44M), average EBITDA is $-62.206M (high $-60.431M, low $-65.504M), average net income is $-49.39M (high $-44.74M, low $-56.04M), average SG&A $147.24M (high $155.05M, low $143.04M), and average EPS is $-0.283 (high $-0.257, low $-0.321). OPTN's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $101.3M (high $110M, low $96.39M), average EBITDA is $-78.045M (high $-74.261M, low $-84.744M), average net income is $-12.206M (high $-10.828M, low $-14.177M), average SG&A $184.73M (high $200.59M, low $175.77M), and average EPS is $-0.07 (high $-0.0621, low $-0.0813).

Did the OPTN's actual financial results beat the analysts' financial forecasts?

Based on OptiNose's last annual report (Dec 2023), the company's revenue was $70.99M, beating the average analysts forecast of $65.15M by 8.95%. Apple's EBITDA was $-22.748M, missing the average prediction of $-50.197M by -54.68%. The company's net income was $-35.483M, missing the average estimation of $-74.907M by -52.63%. Apple's SG&A was $79.8M, missing the average forecast of $118.82M by -32.84%. Lastly, the company's EPS was $-0.0003, missing the average prediction of $-0.43 by -99.93%. In terms of the last quarterly report (Dec 2023), OptiNose's revenue was $19.86M, beating the average analysts' forecast of $19.26M by 3.12%. The company's EBITDA was $-4.948M, missing the average prediction of $-14.841M by -66.66%. OptiNose's net income was $-10.161M, missing the average estimation of $-15.118M by -32.79%. The company's SG&A was $18.96M, missing the average forecast of $35.13M by -46.03%. Lastly, the company's EPS was $-0.0001, missing the average prediction of $-0.0867 by -99.88%